Centre for Agriculture and the Bioeconomy, Queensland University of Technology (QUT), Brisbane, QLD 4000, Australia.
ARC Centre of Excellence for Plant Success in Nature and Agriculture, Queensland University of Technology (QUT), Brisbane, QLD 4000, Australia.
Viruses. 2020 Dec 22;13(1):5. doi: 10.3390/v13010005.
Severe virus outbreaks are occurring more often and spreading faster and further than ever. Preparedness plans based on lessons learned from past epidemics can guide behavioral and pharmacological interventions to contain and treat emergent diseases. Although conventional biologics production systems can meet the pharmaceutical needs of a community at homeostasis, the COVID-19 pandemic has created an abrupt rise in demand for vaccines and therapeutics that highlight the gaps in this supply chain's ability to quickly develop and produce biologics in emergency situations given a short lead time. Considering the projected requirements for COVID-19 vaccines and the necessity for expedited large scale manufacture the capabilities of current biologics production systems should be surveyed to determine their applicability to pandemic preparedness. Plant-based biologics production systems have progressed to a state of commercial viability in the past 30 years with the capacity for production of complex, glycosylated, "mammalian compatible" molecules in a system with comparatively low production costs, high scalability, and production flexibility. Continued research drives the expansion of plant virus-based tools for harnessing the full production capacity from the plant biomass in transient systems. Here, we present an overview of vaccine production systems with a focus on plant-based production systems and their potential role as "first responders" in emergency pandemic situations.
严重的病毒爆发比以往任何时候都更加频繁和迅速地传播。基于从过去的流行病中吸取的经验教训制定的准备计划，可以指导行为和药物干预措施，以控制和治疗突发疾病。虽然传统的生物制品生产系统可以满足社区在稳定状态下的药物需求，但 COVID-19 大流行导致对疫苗和疗法的需求突然增加，这凸显了供应链在短时间内快速开发和生产生物制品的能力存在差距。考虑到 COVID-19 疫苗的预计需求以及加快大规模生产的必要性，应该调查当前生物制品生产系统的能力，以确定它们在大流行准备方面的适用性。在过去的 30 年中，植物生物制品生产系统已经发展到商业可行性的阶段，具有在生产成本相对较低、可扩展性高和生产灵活性强的系统中生产复杂的、糖基化的、“与哺乳动物兼容”的分子的能力。持续的研究推动了利用瞬时系统中的植物生物质的全部生产能力的植物病毒工具的扩展。在这里，我们概述了疫苗生产系统，重点介绍了基于植物的生产系统及其在紧急大流行情况下作为“第一响应者”的潜在作用。
